These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2223392)

  • 1. Antimetabolites.
    Allegra CJ; Grem JL; Chu E; Johnston P; Yeh GC; Chabner BA
    Cancer Chemother Biol Response Modif; 1990; 11():1-28. PubMed ID: 2223392
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimetabolites.
    Johnston PG; Takimoto CH; Grem JL; Chabner BA; Allegra CJ; Chu E
    Cancer Chemother Biol Response Modif; 1996; 16():1-27. PubMed ID: 8639379
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer chemotherapy and biological response modifiers annual 16. Introduction.
    Pinedo HM; Longo DL; Chabner BA
    Cancer Chemother Biol Response Modif; 1996; 16():xvii-xviii. PubMed ID: 8639378
    [No Abstract]   [Full Text] [Related]  

  • 4. Antimetabolites.
    Chu E; Johnston PG; Takimoto CH; Politi PM; Grem JL; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1993; 14():1-25. PubMed ID: 8312100
    [No Abstract]   [Full Text] [Related]  

  • 5. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)1: antitumor effect and mechanism of action.
    Azuma A; Matsuda A; Sasaki T; Fukushima M
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):609-19. PubMed ID: 11563078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimetabolites.
    Allegra CJ; Baram J; Chabner BA; Yeh GC; Aiba K; Curt GA
    Cancer Chemother Biol Response Modif; 1987; 9():1-22. PubMed ID: 2484324
    [No Abstract]   [Full Text] [Related]  

  • 7. Antimetabolites.
    Johnston PG; Takimoto CH; Grem JL; Fidias P; Grossbard ML; Chabner BA; Allegra CJ; Chu E
    Cancer Chemother Biol Response Modif; 1997; 17():1-39. PubMed ID: 9551206
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine.
    Bijnsdorp IV; Schwendener RA; Schott H; Schott S; Fichtner I; Honeywell RJ; Losekoot N; Laan AC; Peters GJ
    Nucleic Acids Symp Ser (Oxf); 2008; (52):651. PubMed ID: 18776548
    [No Abstract]   [Full Text] [Related]  

  • 9. Properties of purine and pyrimidine analogs.
    Hitchings GH
    Adv Enzyme Regul; 1991; 31():433-43. PubMed ID: 1877398
    [No Abstract]   [Full Text] [Related]  

  • 10. Antimetabolites.
    Allegra CJ; Grem JL; Yeh GC; Chabner BA
    Cancer Chemother Biol Response Modif; 1988; 10():1-22. PubMed ID: 3079379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclopentenyl cytosine increases the phosphorylation and incorporation into dna of arabinofu-ranosyl cytosine in a myeloid leukemic cell-line.
    Verschuur AC; van Gennip AH; Leen R; Voûte PA; van Kuilenburg AB
    Adv Exp Med Biol; 2000; 486():311-7. PubMed ID: 11783507
    [No Abstract]   [Full Text] [Related]  

  • 12. Methotrexate.
    Held-Warmkessel J
    Clin J Oncol Nurs; 2000; 4(4):187-8. PubMed ID: 11261104
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of various purine and pyrimidine bases on the metachronosis of vibration].
    Chauchard P
    C R Seances Soc Biol Fil; 1969; 163(5):1046-7. PubMed ID: 4259155
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II].
    Grignani F; Martelli M; Tonato M
    Clin Ter; 1974 Apr; 69(2):153-76. PubMed ID: 4134598
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance mechanisms to methotrexate in tumors.
    Bertino JR; Göker E; Gorlick R; Li WW; Banerjee D
    Stem Cells; 1996 Jan; 14(1):5-9. PubMed ID: 8820944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimetabolites.
    Schornagel JH
    Curr Opin Oncol; 1989 Dec; 1(2):179-85. PubMed ID: 2489957
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimetabolites reduce the activities of enzymes with short half-lives in addition to inhibiting their specific targets.
    Weber G; Prajda N; Singhal RL
    Adv Exp Med Biol; 1994; 370():145-50. PubMed ID: 7660878
    [No Abstract]   [Full Text] [Related]  

  • 18. Antimetabolites.
    Chu E; Johnston PG; Grem JL; Takimoto CH; Van Groeningen C; Chabner BA; Allegra CJ
    Cancer Chemother Biol Response Modif; 1994; 15():1-31. PubMed ID: 7779582
    [No Abstract]   [Full Text] [Related]  

  • 19. The molecular perspective: methotrexate.
    Goodsell DS
    Oncologist; 1999; 4(4):340-1. PubMed ID: 10476546
    [No Abstract]   [Full Text] [Related]  

  • 20. Biochemical approach to new medications.
    Hitchings GH
    Adv Exp Med Biol; 1991; 309A():1-6. PubMed ID: 1789185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.